TB

TB Strategic Investment Information Note, the Global Fund, 2014

The purpose of this framework is to help guide countries to choose what to invest in for tuberculosis (TB) prevention, care and control. It is intended to be mostly used in the context of a request for support to the Global Fund. It aims to promote strategic investments, that is, investment in activities that will have the greatest impact, especially for key affected populations. The framework therefore contains recommendations on how to set priorities and target TB interventions to achieve the highest impact, based on the TB profile and the health system context of a country. It is designed to be used by countries that are preparing their national strategic plans (NSP) for TB control, and as a complement to other guidance and tools for TB strategic planning and interventions. For those countries that already have an NSP, this note is particularly useful for country dialogue and preparation of the concept note for Global Fund investment. The concept note replaces previous Global Fund proposal documents and is the principal means to request and access funding under the new funding model of the Global Fund. 

Developing Tuberculosis Services for People Who Use Drugs: Training manual, EHRN, 2013

This manual aims to contribute to the comprehensive response to HIV, TB and drug use and support linkages between HIV prevention, TB control and harm reduction strategies and services in Eastern Europe and Central Asia. It compiles clinical and programmatic information about TB, HIV and drug use aligned with the most recent normative guidance issued by WHO.  The goal of the manual is to increase the capacity to provide quality TB-related services for people who inject drugs and are living with HIV.  Although the training manual might be useful for all stakeholders involved in harm reduction and TB programs as an information resource, it is primarily designed for trainers developing and delivering trainings to civil society, community and health care workers in the field of harm reduction, TB and HIV. 

Consolidated action plan to prevent and combat multidrug and extensively drug-resistant tuberculosis in the WHO European Region 2011–2015, Regional Committee for Europe, 2011

The WHO Regional Office for Europe has launched an action plan to contain the spread of drug- resistant TB in the region by the end of 2015.  This action plan was prepared in consultation with representatives of the 53 countries of the WHO European Region, experts, patients and communities affected by the disease. The plan takes into account new diagnostic techniques, patient-centered models of care and services tailored to special populations. It includes six strategic directions, such as collaboration on more effective drugs, vaccines and testing, and seven areas of intervention, such as improving access to testing and treatment. If fully implemented, the plan is expected, by 2015, to diagnose 225,000 MDR-TB patients within three days of presenting to a healthcare service with TB symptoms, to successfully treat 127,000 MDR-TB patients, and to prevent the emergence of 250,000 new MDR-TB and 13,000 new XDR-TB cases. 

Медицинская помощь больным с «тройным диагнозом» (туберкулез, ВИЧ-инфекция и опиоидная зависимость): сборник статей для фтизиатров, инфекционистов, психиатров-наркологов, Амирович, Д., и др., 2013

Данная публикация неправительственной организации "ЮЛА" освещает проблематику тройного диагноза (наркозависимость, ВИЧ/СПИД, туберкулез) и необходимость интегрированного подхода в системе существующих структур здравоохранения Российской Федерации.  Сборник статей включает статьи по  трем заболеваниям: туберкулез, ВИЧ, опиоидная зависимость. Он является одной из первых попыток представить российским врачам- фтизиатрам, инфекционистам, психиатрам-наркологам проблематику ситуации и предоставить информацию о  современных методах лечения ТБ, ВИЧ и опиоидной зависимости с учетом специфики тройного диагноза.  Сборник предназначен прежде всего для врачей-фтизиатров, инфекционистов, психиатров-наркологов, но  будет также полезен всем специалистам, которые работают в этой области.

Tuberculosis: Voices in the fight against the European epidemic, GHA, RESULTS UK, ACTION, TBEC, 2013

This report prepared by the ACTION Partnership—a network of civil society advocacy organizations working to mobilize new resources against tuberculosis (TB)—aims to give TB a ‘human face’ by looking behind the statistics to focus on the every-day challenges faced by patients and their caregivers. Their personal stories should inform any policy change and must be taken into account by local governments in order to achieve a comprehensive TB response that respects the rights of the patients.

Tuberculosis surveillance and monitoring in Europe, WHO, ECDC, 2012

As in the previous years, surveillance of tuberculosis (TB) reveals a mixed epidemiological picture among the Member States of the WHO European Region. Member States in the east have much higher notification rates than the west. Although the Region comprises only 4.7% of the world’s newly detected and relapsed TB cases, it reported 309 648 new episodes of TB (34.0 per 100 000 population) out of 418 000 (range 355 000–496 000) estimated cases (47 cases per 100 000 population (range 40–55), and maintained a high case detection rate of 74% (range 63–87%). This demonstrates that the countries in the WHO European Region are leading the way in their management of a highly sensitive routine surveillance system. More than 60 000 (40 000–90 000) deaths in the Region were estimated as being due to TB, representing 6.7 cases per 100 000 population.

Bridging The Gap: How the European Union Can Address the Funding Crisis for TB and HIV Programmes in Eastern Europe and Central Asia, Warwick, B., et al., TBEC, 2013

This report examines the funding gaps for TB and HIV programs in Eastern Europe and Central Asia (EECA).  It follows up on an earlier report “Bridging the Gap: Why the European Union must address the Global Fund’s funding crisis to tackle the escalating HIV and TB epidemics in Eastern Europe and Central Asia”, which was first published in September 2012 and described the challenges many EECA countries faced in the aftermath of the decision by the Global Fund to Fight AIDS, Tuberculosis and Malaria to cancel Round 11. Since then, available funding for TB and HIV programs continues to be limited, with many donors, including the Global Fund, scaling back their support to middle-income countries. Domestic support for HIV prevention programs for vulnerable populations has also been lacking. The report presents three case studies – from Azerbaijan, Albania and Romania – that outline ongoing challenges in the fight against TB and HIV and make the case for a regional response to these epidemics by the Global Fund and the European Union institutions.

Roadmap to Prevent and Combat Drug - Resistant Tuberculosis, World Health Organization, 2011

In response to the alarming problem of multidrug- and extensively drug-resistant tuberculosis (M/XDR-TB) in the WHO European Region, and in order to scale up a comprehensive response and to prevent and control M/XDR-TB, a consolidated action plan has been developed for 2011–2015 for all 53 Member States of the WHO European Region and partners. The Plan was endorsed by the sixty-first session of the WHO Regional Committee in Baku on 15 September 2011. It has six strategic directions and seven areas of intervention. The strategic directions are cross-cutting and highlight the corporate priori- ties of the Region. 

Bridging the Gap: Why the European Union Must Address the Global Fund’s Funding Crisis to Tackle the Escalating HIV and TB epidemics in Eastern Europe and Central Asia, The Global Fund, 2012

Despite its tremendous success, the Global Fund to Fight AIDs, Tuberculosis and Malaria is currently facing serious funding gaps. As a result, in December 2011 the Global Fund was forced to cancel its next funding round, leaving recipient countries without the financial support needed to combat their disease epidemics. Furthermore, the funding crisis will leave civil society organisations without the resources needed to hold national governments to account and to create national buy-in to fund disease responses with domestic resources.

Pages